NCT01914510View on ClinicalTrials.gov

A Study of ENMD-2076 in Ovarian Clear Cell Cancers

PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

September 30, 2013

Primary Completion Date

January 31, 2017

Study Completion Date

January 31, 2017

Conditions
Ovarian Clear Cell Carcinoma
Interventions
DRUG

ENMD-2076

Trial Locations (6)

T2N 4N2

Tom Baker Cancer Centre, Calgary

T6G 1Z2

Cross Cancer Institute, Edmonton

V5Z 4E6

British Columbia Cancer Agency, Vancouver

N6A 4L6

London Regional Cancer Program, London

K1H 8L6

Ottawa Regional Cancer Centre, Ottawa

M5G 2M9

Princess Margaret Cancer Centre, Toronto

All Listed Sponsors
lead

University Health Network, Toronto

OTHER

NCT01914510 - A Study of ENMD-2076 in Ovarian Clear Cell Cancers | Biotech Hunter | Biotech Hunter